These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

193 related items for PubMed ID: 16786129

  • 1. Acquired resistance to imatinib and secondary KIT exon 13 mutation in gastrointestinal stromal tumour.
    Bertucci F, Goncalves A, Monges G, Madroszyk A, Guiramand J, Moutardier V, Noguchi T, Dubreuil P, Sobol H.
    Oncol Rep; 2006 Jul; 16(1):97-101. PubMed ID: 16786129
    [Abstract] [Full Text] [Related]

  • 2. A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors.
    Chen LL, Trent JC, Wu EF, Fuller GN, Ramdas L, Zhang W, Raymond AK, Prieto VG, Oyedeji CO, Hunt KK, Pollock RE, Feig BW, Hayes KJ, Choi H, Macapinlac HA, Hittelman W, Velasco MA, Patel S, Burgess MA, Benjamin RS, Frazier ML.
    Cancer Res; 2004 Sep 01; 64(17):5913-9. PubMed ID: 15342366
    [Abstract] [Full Text] [Related]

  • 3. Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options.
    Demetri GD.
    Semin Oncol; 2001 Oct 01; 28(5 Suppl 17):19-26. PubMed ID: 11740803
    [Abstract] [Full Text] [Related]

  • 4. Pathologic and molecular heterogeneity in imatinib-stable or imatinib-responsive gastrointestinal stromal tumors.
    Agaram NP, Besmer P, Wong GC, Guo T, Socci ND, Maki RG, DeSantis D, Brennan MF, Singer S, DeMatteo RP, Antonescu CR.
    Clin Cancer Res; 2007 Jan 01; 13(1):170-81. PubMed ID: 17200352
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Secondary C-kit mutation is a cause of acquired resistance to imatinib in gastrointestinal stromal tumor.
    Zheng S, Pan YL, Tao DY, Wang JL, Huang KE.
    Scand J Gastroenterol; 2009 Jan 01; 44(6):760-3. PubMed ID: 19096980
    [Abstract] [Full Text] [Related]

  • 12. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours.
    Lasota J, Miettinen M.
    Histopathology; 2008 Sep 01; 53(3):245-66. PubMed ID: 18312355
    [Abstract] [Full Text] [Related]

  • 13. Current clinical management of gastrointestinal stromal tumors.
    Tosoni A, Nicolardi L, Brandes AA.
    Expert Rev Anticancer Ther; 2004 Aug 01; 4(4):595-605. PubMed ID: 15270663
    [Abstract] [Full Text] [Related]

  • 14. [A case of metastatic gastrointestinal stromal tumor developing a resistance to STI571 (imatinib mesylate)].
    Miyake M, Takeda Y, Hasuike Y, Kashiwazaki M, Mishima H, Ikenaga M, Mano M, Takada Y, Hirota S, Tsujinaka T.
    Gan To Kagaku Ryoho; 2004 Oct 01; 31(11):1791-4. PubMed ID: 15553717
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Effects of imatinib vary with the types of KIT-mutation in gastrointestinal stromal tumor cell lines.
    Noma K, Naomoto Y, Gunduz M, Matsuoka J, Yamatsuji T, Shirakawa Y, Nobuhisa T, Okawa T, Takaoka M, Tomono Y, Hiroyuki O, Gunduz E, Tanaka N.
    Oncol Rep; 2005 Sep 01; 14(3):645-50. PubMed ID: 16077968
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway.
    Bauer S, Duensing A, Demetri GD, Fletcher JA.
    Oncogene; 2007 Nov 29; 26(54):7560-8. PubMed ID: 17546049
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.